As patients with cancer live longer and the disease becomes a chronic disease for many, it becomes important for providers to understand how the needs of the patient change from being newly diagnosed to active therapy to long-term therapy, explained Linda House, president of the Cancer Support Community.
As patients with cancer live longer and the disease becomes a chronic disease for many, it becomes important for providers to understand how the needs of the patient change from being newly diagnosed to active therapy to long-term therapy, explained Linda House, president of the Cancer Support Community.
Transcript (slightly modified)
With innovations in care, cancer is being viewed more as a chronic condition, does that change patient advocacy?
As cancer becomes more of a chronic condition we really need to take a look at the specific needs of patients along that whole continuum. So, being really thoughtful to understand that what a patient needs when they're newly diagnosed may not in fact be what they need when they're converting from active therapy to long-term therapy. And it may not be what they need when they're trying to live with long-term side effects, for example.
As a patient advocate organization, it behooves us to teach the patients how to advocate for themselves. So as you're thinking about self navigation, what questions do you ask, what resources do you seek out, how do you cope with each of those steps along the way?
And we all really owe it to patients to do this in an evidence-based way. So we have a cancer experience registry where we now have about 8000 who document what that experience looks like. We'll share that with anybody, so as you think about creating solutions, it's really evidence-based on the needs of the patient.
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More
Navigating the Mental Health Challenges of Cancer Diagnosis, Treatment, and Survivorship
March 12th 2024Stress has potential links to worse outcomes in cancer, such as decreased quality of life and greater risks of disease progression and metastasis. There is a complex mix of emotions patients with cancer experience.
Read More